Compare IPHA & ACR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPHA | ACR |
|---|---|---|
| Founded | 1999 | 2005 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.3M | 146.1M |
| IPO Year | 2014 | 2005 |
| Metric | IPHA | ACR |
|---|---|---|
| Price | $2.23 | $14.85 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 1 |
| Target Price | $5.75 | ★ $24.50 |
| AVG Volume (30 Days) | ★ 172.7K | 31.1K |
| Earning Date | 03-26-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $79,946,000.00 |
| Revenue This Year | $180.36 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.18 | $13.83 |
| 52 Week High | $2.71 | $24.61 |
| Indicator | IPHA | ACR |
|---|---|---|
| Relative Strength Index (RSI) | 57.37 | 38.98 |
| Support Level | $1.68 | $13.83 |
| Resistance Level | $2.66 | $18.56 |
| Average True Range (ATR) | 0.15 | 0.72 |
| MACD | 0.01 | 0.09 |
| Stochastic Oscillator | 54.50 | 54.02 |
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
ACRES Commercial Realty Corp is a commercial real estate investment trust that focuses on originating, holding, and managing commercial real estate (CRE) mortgage loans and equity investments in commercial real estate properties through direct ownership and joint ventures. The company invests in commercial real-estate-related assets, including whole loans, A notes, B notes, mezzanine loans, and mortgage-related securities, as well as commercial finance assets, which include other asset-backed securities, senior secured corporate loans, equipment leases and notes, trust preferred securities, debt tranches of collateralized debt obligations, and private equity investments mainly issued by financial institutions.